{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:08:30Z","timestamp":1791472110985,"version":"4.3.4"},"reference-count":28,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100018592","name":"Celltrion","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therap Adv Gastroenterol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Infliximab (IFX) and vedolizumab (VDZ), frequently used biologics in inflammatory bowel disease (IBD), are available as intravenous (IV) and subcutaneous (SC) formulations; however, comparative data are limited.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objectives:<\/jats:title>\n            <jats:p>To compare the rates of discontinuation due to lack of efficacy during maintenance treatment with infliximab (subcutaneous) and vedolizumab (intravenous and subcutaneous) in patients with moderate-to-severe IBD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Design:<\/jats:title>\n            <jats:p>Systematic literature review and meta-analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Data sources and methods:<\/jats:title>\n            <jats:p>Three medical databases, PubMed, Embase, and the Cochrane Library, were systematically searched from January 2010 to May 2024 to identify phases I\u2013III randomized controlled trials. The primary outcome was discontinuation of study drug due to lack of efficacy (per definitions used in the included studies) during maintenance treatment (PROSPERO number CRD42023438330). Rates of discontinuation due to adverse events during maintenance treatment were examined in additional exploratory analyses.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>We identified three eligible clinical trials in IBD for subcutaneous infliximab (591 patients) and five for vedolizumab (intravenous and subcutaneous formulations; 2117 patients). Rates of discontinuation due to lack of efficacy (per individual study definition) were significantly lower in patients treated with subcutaneous infliximab (0.05 (95% confidence interval (CI): 0.03, 0.06)) than in patients treated with vedolizumab (0.29 (95% CI: 0.20, 0.38)); rates remained significantly lower with subcutaneous infliximab versus vedolizumab, respectively, in the subgroups of patients with Crohn\u2019s disease (0.05 (95% CI: 0.02, 0.07) vs 0.37 (95% CI: 0.27, 0.47)) or ulcerative colitis (0.05 (95% CI: 0.02, 0.07) vs 0.24 (95% CI: 0.11, 0.36)). Rates of discontinuation due to adverse events were lower in subcutaneous infliximab-treated patients (0.04 (95% CI: 0.02, 0.05) than in vedolizumab-treated patients (0.08 (95% CI: 0.05, 0.11)).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>In this meta-analysis, rates of discontinuation due to lack of efficacy during maintenance treatment were lower with subcutaneous infliximab than with vedolizumab (intravenous and subcutaneous formulations) in patients with moderate-to-severe IBD.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration:<\/jats:title>\n            <jats:p>PROSPERO number CRD42023438330.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1177\/17562848251383767","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T08:45:23Z","timestamp":1759913123000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment discontinuation rates due to lack of efficacy through 1 year of maintenance treatment with vedolizumab or subcutaneous infliximab in patients with inflammatory bowel disease: a systematic literature review and meta-analysis"],"prefix":"10.1177","volume":"18","author":[{"given":"Marc","family":"Ferrante","sequence":"first","affiliation":[{"name":"Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium"},{"name":"Department of Chronic Diseases and Metabolism, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2536-6618","authenticated-orcid":false,"given":"Laurent","family":"Peyrin-Biroulet","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, INFINY Institute, FHU-CURE, INSERM NGERE, Nancy University Hospital, Vand\u0153uvre-l\u00e8s-Nancy, France"},{"name":"Groupe Hospitalier Priv\u00e9 Ambroise Par\u00e9\u2013Hartmann, Neuilly-sur-Seine, France"},{"name":"Division of Gastroenterology and Hepatology, McGill University Health Centre, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Perttu","family":"Arkkila","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Helsinki University, Helsinki, Finland"},{"name":"Helsinki University Hospital, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Armuzzi","sequence":"additional","affiliation":[{"name":"IBD Center, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy"},{"name":"Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fr\u00e9d\u00e9ric","family":"Colombel","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Gastroenterology and Endoscopy, University Vita-Salute San Raffaele, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Faggiani","sequence":"additional","affiliation":[{"name":"Gastroenterology Department, San Camillo Hospital, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Guardiola","sequence":"additional","affiliation":[{"name":"Digestive Diseases Department, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL, University of Barcelona, L\u2019Hospitalet de Llobregat, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"Hanauer","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorgen","family":"Jahnsen","sequence":"additional","affiliation":[{"name":"Institute of Clinical Medicine\/Department of Gastroenterology, University of Oslo\/Akershus University Hospital, Oslo, Norway"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Reinisch","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2840-0108","authenticated-orcid":false,"given":"Xavier","family":"Roblin","sequence":"additional","affiliation":[{"name":"University Hospital of Saint-Etienne, Saint-Etienne, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip J.","family":"Smith","sequence":"additional","affiliation":[{"name":"Honorary Consultant Gastroenterologist, Department of Gastroenterology, Royal Liverpool Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taek","family":"Sang Kwon","sequence":"additional","affiliation":[{"name":"Celltrion, Inc., Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seungmin","family":"Kim","sequence":"additional","affiliation":[{"name":"Celltrion, Inc., Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoungwan","family":"Nam","sequence":"additional","affiliation":[{"name":"Celltrion, Inc., Incheon, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8556-8433","authenticated-orcid":false,"given":"Raja","family":"Atreya","sequence":"additional","affiliation":[{"name":"Medical Department 1, University Hospital Erlangen, Friedrich-Alexander-University of Erlangen-N\u00fcrnberg, Ulmenweg 18, 91054 Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjz180"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab178"},{"key":"e_1_3_5_4_2","unstructured":"European Medicines Agency. Entyvio: summary of product characteristics https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/entyvio-epar-product-information_en.pdf (accessed 30 September 2024)."},{"key":"e_1_3_5_5_2","unstructured":"European Medicines Agency. Remsima: summary of product characteristics https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/remsima-epar-product-information_en.pdf (accessed 30 September 2024)."},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905725"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/MOG.0000000000000854"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2022-328052"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izac103"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00312-5"},{"key":"e_1_3_5_11_2","unstructured":"United States Food and Drug Administration. Zymfentra prescribing information https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761358s000lbl.pdf (accessed 30 September 2024)."},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.05.006"},{"key":"e_1_3_5_13_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.","journal-title":"BMJ"},{"key":"e_1_3_5_14_2","unstructured":"Higgins JPT Thomas J Chandler J et al. Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). https:\/\/training.cochrane.org\/handbook (accessed September 2024)."},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-019-01647-w"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212989"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.5217\/ir.2020.00026"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2021.02.068"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215739"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab133"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"issue":"3","key":"e_1_3_5_22_2","article-title":"Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis","volume":"158","author":"Sandborn WJ","year":"2020","unstructured":"Sandborn WJ, Baert F, Danese S, et al. Efficacy and safety of vedolizumab subcutaneous formulation in a randomized trial of patients with ulcerative colitis. Gastroenterology 2020; 158(3): 562\u2013572.e12.","journal-title":"Gastroenterology"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756284820981216"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-022-02347-1"},{"issue":"4","key":"e_1_3_5_25_2","first-page":"2021","article-title":"Persistence, dosing, and other treatment patterns among Crohn\u2019s disease patients initiating biologics in United States","volume":"360","author":"Teeple A","unstructured":"Teeple A, Sah J, Mallampati R, et al. Persistence, dosing, and other treatment patterns among Crohn\u2019s disease patients initiating biologics in United States. Crohns Colitis 360 2021; 3(4): otab076.","journal-title":"Crohns Colitis"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2071041"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-28907-3"},{"issue":"2","key":"e_1_3_5_28_2","first-page":"2019","article-title":"Comparison of real-world treatment outcomes with vedolizumab versus infliximab in biologic-naive patients with inflammatory bowel disease","volume":"360","author":"Patel H","unstructured":"Patel H, Latremouille-Viau D, Burne R, et al. Comparison of real-world treatment outcomes with vedolizumab versus infliximab in biologic-naive patients with inflammatory bowel disease. Crohns Colitis 360 2019; 1(2): otz022.","journal-title":"Crohns Colitis"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04523.x"}],"container-title":["Therapeutic Advances in Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848251383767","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562848251383767","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562848251383767","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:40:13Z","timestamp":1760276413000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562848251383767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":28,"alternative-id":["10.1177\/17562848251383767"],"URL":"https:\/\/doi.org\/10.1177\/17562848251383767","relation":{},"ISSN":["1756-2848","1756-2848"],"issn-type":[{"value":"1756-2848","type":"print"},{"value":"1756-2848","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"article-number":"17562848251383767"}}